The Canadian Registry for Pulmonary Fibrosis (CARE-PF) enrolled in its first 18 months more than 1,200 people with interstitial lung disease (ILD), with more than half having either idiopathic pulmonary fibrosis (IPF) or connective tissue disease-associated interstitial lung disease (CTD-ILD). Data collected through the CARE-PF registry could be useful…
News
Algernon Pharmaceuticals‘s NP-120 (ifenprodil) outperformed Merck‘s MK-7264 (gefapixant) in an animal model of acute cough, a preclinical study by a contract research organization (CRO) shows. NP-120 is Algernon’s repurposed lead candidate for the treatment of idiopathic pulmonary fibrosis (IPF), while MK-7264 is Merck’s lead candidate for the treatment…
Enrollment in the Phase 2 clinical trial of setanaxib (GKT831), an oral investigational treatment for idiopathic pulmonary fibrosis (IPF), will start in the coming weeks, Genkyotex announced in a progress report. Following approval by the U.S. Food and Drug Administration (FDA) in July, the study protocol now…
Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s highest-ranking health official said. “We have to think about how our financing system can protect those with serious and rare illnesses.
A joint research project between BioMed X and Boehringer Ingelheim has identified a new set of potential epigenetic targets for the treatment of two chronic lung diseases, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). Epigenetics refers to DNA chemical modifications that can turn genes on or…
Treatment with Esbriet (pirfenidone) before and after cancer removal surgery reduces the risks of acute flares following the procedure in people with idiopathic pulmonary fibrosis (IPF) and lung cancer, a study finds. The findings were reported in “Perioperative pirfenidone treatment for lung cancer patients with…
Idebenone, an antioxidant molecule used to treat Alzheimer’s disease and other brain-damaging conditions, prevented lung damage in a mouse model of pulmonary fibrosis (PF), a study has found. The therapy also improved lung function in mice that had already developed the disease. The study, “…
Algernon Pharmaceuticals has announced its plans to launch its first Phase 2 clinical trial evaluating one of two repurposed compounds — NP-120 for the treatment of idiopathic pulmonary fibrosis (IPF) or NP-178 for inflammatory bowel disease (IBD) — in the second quarter of 2020. This follows…
Patients with idiopathic pulmonary fibrosis (IPF) in Canada face challenges in equal access to quality healthcare services at the national level, with drastic differences between provinces, according to the findings of a new report from the Canadian Pulmonary Fibrosis Foundation (CPFF) and Hoffmann-La Roche. The report, titled…
Delays in diagnosis and difficulty getting timely access to appropriate specialist care and treatment were highlighted as major gaps in care in a recent survey of people with pulmonary fibrosis (PF) and their healthcare providers. The survey results were discussed in the journal ERJ Open Research in a study,…
